Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
581-600 of 604 trials

Intestinal Failure-Associated Liver Disease: NST-6179 Study

We are testing a new oral medication, NST-6179, for individuals with Intestinal Failure-Associated Liver Disease. The study aims to understand its safety and how it affects liver health.

Intestinal Failure-Associated Liver Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterologyHepatology

Multiple Sclerosis: THC/CBD Oral Solution

We are studying an oral solution of THC and CBD for people with multiple sclerosis to see if it helps relieve chronic pain and improve other symptoms. This trial compares the treatment to a placebo to assess its effects.

Chronic Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Chronic Cluster Headache: Low-Dose LSD Study

We are investigating whether a low dose of LSD can help reduce the frequency and severity of chronic cluster headaches. This study will assess both its effectiveness and safety compared to a placebo.

Chronic Cluster Headache≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Bone Health: Everolimus and Exercise for Postmenopausal Women

We are studying if a combination of a medication and resistance training can improve bone formation in healthy postmenopausal women. This research may help in understanding better ways to support bone health.

Healthy Elderly Women3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementGynecology and ObstetricsOrthopedics and Traumatology

Advanced Solid Tumors: EIK1004 Treatment Study

We are testing a new treatment called EIK1004 for people with advanced solid tumors to see how safe it is and if it may help reduce tumor activity. This study will help us understand the best dose and its effects.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Heart Health: Orticumab for Inflammation After Heart Attack

We are studying whether orticumab can reduce inflammation in people who have had a heart attack and show elevated coronary inflammation. The trial will also evaluate the safety of this treatment.

Heart Attack6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Chronic Obstructive Pulmonary Disease: AZD6793 Tablets

We are investigating whether AZD6793 can help reduce flare-ups in adults with moderate to very severe COPD. The study will also look at its effects on lung function and overall health.

Chronic Obstructive Pulmonary Disease (COPD)6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePulmonology

Heart Disease: AZD0780 Medication Study

We are testing whether AZD0780 can help reduce serious heart and vascular problems in patients with existing heart disease or those at high risk. This study compares AZD0780 to a placebo to see which is more effective.

Atherosclerotic Cardiovascular DiseaseConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

High 'Bad' Cholesterol: AZD0780 Study

We are investigating how well AZD0780 works for adults with high LDL cholesterol and heart disease or at risk for it. The goal is to see if it can lower cholesterol levels more effectively than a placebo.

High CholesterolAtherosclerotic Cardiovascular Disease1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Kidney Transplant: Reduced Immunosuppression for Older Adults

We are studying whether a lower dose of immunosuppressive medication is as effective and safe as the standard dose for older adults after kidney transplantation. This may help improve their overall health and quality of life.

End-stage Renal Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Glioblastoma: Intraoperative Photodynamic Therapy with Pentalafen®

We are studying a new light-based treatment for adults with grade IV glioblastoma during surgery. The goal is to evaluate its safety and how well it works in reducing tumor response.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Dengue Vaccine Qdenga: Antibody Response Study

We are examining how the Qdenga vaccine affects antibody levels for other flavivirus infections in Swedish travelers. This study aims to see if vaccination leads to higher antibody levels that could interfere with diagnostic tests.

Healthy Participants3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesAllergologyHematologyInfectious Diseases

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Inflammatory Rheumatic Diseases: JAK Inhibitor Dose Reduction Study

We are exploring if lowering the dose of JAK inhibitors is as effective as keeping the current dose for patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis in low disease activity. This study will also look at safety and how many patients can successfully reduce their medication.

Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Idiopathic Hypersomnia: ALKS 2680 Study

We are evaluating a new medication, ALKS 2680, for individuals with Idiopathic Hypersomnia to see if it helps reduce excessive daytime sleepiness and is safe to use.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Congenital Pseudarthrosis of the Tibia: NVD003 Treatment Study

We are evaluating how effective and safe NVD003 is for children undergoing surgery for congenital pseudarthrosis of the tibia. The study will also look at its impact on bone healing and quality of life.

Congenital Pseudarthrosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Atrial Fibrillation: Early Rhythm-Control Therapy for Stroke Prevention

We are studying if starting rhythm-control therapy early helps patients with atrial fibrillation after a stroke avoid further heart problems. This trial also examines the impact on quality of life and treatment costs.

Acute Ischemic Stroke and Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Durvalumab for Limited Stage Small Cell Lung Cancer

We are studying the safety and effectiveness of durvalumab for patients with limited stage small cell lung cancer who have not progressed after chemoradiation therapy. This trial also looks at how the treatment affects quality of life and disease symptoms.

Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Atrial Fibrillation: AP31969 Medication Study

We are testing a new medication, AP31969, for people with atrial fibrillation to see if it helps control their heart rhythm and improve their quality of life. The study will also evaluate the safety of this treatment.

Atrial Fibrillation3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Hereditary Angioedema: Navenibart Treatment Study

We are studying whether navenibart can help prevent attacks in adults and adolescents with hereditary angioedema. The trial will also look at its safety and how it affects quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine